Brazil

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National

Download

Value (%)	Year	Type	Source
3.42 (2.97 - 3.84)	2019	Modelled	IHME
3.51 (3.07 - 3.94)	2018	Modelled	IHME
3.56 (3.09 - 3.99)	2017	Modelled	IHME
3.57 (3.12 - 3.97)	2016	Modelled	IHME
3.58 (3.12 - 3.98)	2015	Modelled	IHME
3.62 (3.16 - 4.01)	2014	Modelled	IHME
3.72 (3.24 - 4.13)	2013	Modelled	IHME
3.84 (3.35 - 4.28)	2012	Modelled	IHME
3.97 (3.45 - 4.44)	2011	Modelled	IHME
4.08 (3.54 - 4.57)	2010	Modelled	IHME
4.17 (3.62 - 4.67)	2009	Modelled	IHME
4.26 (3.70 - 4.76)	2008	Modelled	IHME
4.34 (3.79 - 4.86)	2007	Modelled	IHME
4.43 (3.86 - 4.96)	2006	Modelled	IHME
4.51 (3.93 - 5.06)	2005	Modelled	IHME
4.6 (4.01 - 5.15)	2004	Modelled	IHME
4.69 (4.10 - 5.26)	2003	Modelled	IHME
4.77 (4.17 - 5.36)	2002	Modelled	IHME
4.85 (4.22 - 5.47)	2001	Modelled	IHME
4.91 (4.27 - 5.55)	2000	Modelled	IHME
4.96 (4.31 - 5.60)	1999	Modelled	IHME
5.01 (4.35 - 5.65)	1998	Modelled	IHME
5.05 (4.38 - 5.69)	1997	Modelled	IHME
5.07 (4.40 - 5.72)	1996	Modelled	IHME
5.08 (4.40 - 5.73)	1995	Modelled	IHME
5.09 (4.39 - 5.73)	1994	Modelled	IHME
5.09 (4.39 - 5.73)	1993	Modelled	IHME
5.08 (4.39 - 5.72)	1992	Modelled	IHME
5.08 (4.39 - 5.73)	1991	Modelled	IHME
5.07 (4.38 - 5.74)	1990	Modelled	IHME
7.9 (7 - 8.70)	1999	Survey/reported	Silveira TR et al, 1999
0.54 (0.43 - 0.69)	2015	Modelled	WHO
0.65 (0.65 - 0.66)	2013	Modelled	Schweitzer et al, 2015

Showing out of

Children under-5 years

Download

Value (%)	Year	Type	Source
0.12 (0.10 - 0.16)	2019	Modelled	IHME
0.13 (0.10 - 0.16)	2018	Modelled	IHME
0.13 (0.10 - 0.16)	2017	Modelled	IHME
0.13 (0.10 - 0.16)	2016	Modelled	IHME
0.12 (0.10 - 0.15)	2015	Modelled	IHME
0.12 (0.10 - 0.15)	2014	Modelled	IHME
0.13 (0.10 - 0.16)	2013	Modelled	IHME
0.13 (0.11 - 0.17)	2012	Modelled	IHME
0.14 (0.11 - 0.17)	2011	Modelled	IHME
0.14 (0.11 - 0.18)	2010	Modelled	IHME
0.14 (0.11 - 0.18)	2009	Modelled	IHME
0.15 (0.12 - 0.18)	2008	Modelled	IHME
0.15 (0.12 - 0.18)	2007	Modelled	IHME
0.15 (0.12 - 0.19)	2006	Modelled	IHME
0.15 (0.12 - 0.19)	2005	Modelled	IHME
0.18 (0.14 - 0.22)	2004	Modelled	IHME
0.23 (0.18 - 0.28)	2003	Modelled	IHME
0.3 (0.24 - 0.37)	2002	Modelled	IHME
0.39 (0.31 - 0.49)	2001	Modelled	IHME
0.5 (0.40 - 0.62)	2000	Modelled	IHME
0.73 (0.57 - 0.90)	1999	Modelled	IHME
1.1 (0.87 - 1.37)	1998	Modelled	IHME
1.52 (1.20 - 1.89)	1997	Modelled	IHME
1.88 (1.48 - 2.33)	1996	Modelled	IHME
2.06 (1.63 - 2.57)	1995	Modelled	IHME
2.12 (1.68 - 2.63)	1994	Modelled	IHME
2.17 (1.73 - 2.69)	1993	Modelled	IHME
2.21 (1.76 - 2.74)	1992	Modelled	IHME
2.23 (1.78 - 2.77)	1991	Modelled	IHME
2.24 (1.79 - 2.79)	1990	Modelled	IHME
0.07 (0.05 - 0.11)	2015	Modelled	WHO

Showing out of

HBV-related death rate

National

Download

Value (per 100,000)	Year	Type	Source
2.52 (2.24 - 2.83)	2019	Modelled	IHME
2.47 (2.22 - 2.78)	2018	Modelled	IHME
2.44 (2.19 - 2.72)	2017	Modelled	IHME
2.49 (2.22 - 2.78)	2016	Modelled	IHME
2.46 (2.20 - 2.76)	2015	Modelled	IHME
2.49 (2.24 - 2.78)	2014	Modelled	IHME
2.53 (2.26 - 2.83)	2013	Modelled	IHME
2.57 (2.31 - 2.87)	2012	Modelled	IHME
2.63 (2.36 - 2.93)	2011	Modelled	IHME
2.68 (2.41 - 3)	2010	Modelled	IHME
2.85 (2.57 - 3.18)	2009	Modelled	IHME
3.16 (2.85 - 3.53)	2008	Modelled	IHME
3.5 (3.15 - 3.89)	2007	Modelled	IHME
3.76 (3.38 - 4.18)	2006	Modelled	IHME
3.87 (3.51 - 4.31)	2005	Modelled	IHME
3.95 (3.57 - 4.39)	2004	Modelled	IHME
3.94 (3.56 - 4.37)	2003	Modelled	IHME
3.94 (3.55 - 4.37)	2002	Modelled	IHME
3.94 (3.56 - 4.39)	2001	Modelled	IHME
3.93 (3.55 - 4.35)	2000	Modelled	IHME
3.92 (3.55 - 4.35)	1999	Modelled	IHME
3.9 (3.53 - 4.32)	1998	Modelled	IHME
3.88 (3.52 - 4.30)	1997	Modelled	IHME
3.91 (3.52 - 4.33)	1996	Modelled	IHME
3.91 (3.52 - 4.33)	1995	Modelled	IHME
3.91 (3.54 - 4.35)	1994	Modelled	IHME
3.92 (3.54 - 4.33)	1993	Modelled	IHME
3.83 (3.47 - 4.25)	1992	Modelled	IHME
3.83 (3.46 - 4.25)	1991	Modelled	IHME
3.9 (3.53 - 4.32)	1990	Modelled	IHME

Showing out of

Technical notes

HBV-related deaths

National

Download

Value	Year	Type	Source
5,450 (4,858 - 6,140)	2019	Modelled	IHME
5,316 (4,769 - 5,967)	2018	Modelled	IHME
5,200 (4,659 - 5,803)	2017	Modelled	IHME
5,253 (4,682 - 5,867)	2016	Modelled	IHME
5,156 (4,600 - 5,765)	2015	Modelled	IHME
5,147 (4,631 - 5,751)	2014	Modelled	IHME
5,184 (4,640 - 5,800)	2013	Modelled	IHME
5,207 (4,680 - 5,816)	2012	Modelled	IHME
5,285 (4,731 - 5,887)	2011	Modelled	IHME
5,311 (4,771 - 5,948)	2010	Modelled	IHME
5,581 (5,034 - 6,233)	2009	Modelled	IHME
6,129 (5,521 - 6,829)	2008	Modelled	IHME
6,690 (6,021 - 7,446)	2007	Modelled	IHME
7,108 (6,387 - 7,896)	2006	Modelled	IHME
7,216 (6,546 - 8,035)	2005	Modelled	IHME
7,273 (6,581 - 8,076)	2004	Modelled	IHME
7,159 (6,474 - 7,936)	2003	Modelled	IHME
7,057 (6,354 - 7,837)	2002	Modelled	IHME
6,958 (6,301 - 7,765)	2001	Modelled	IHME
6,841 (6,185 - 7,578)	2000	Modelled	IHME
6,734 (6,094 - 7,470)	1999	Modelled	IHME
6,598 (5,971 - 7,312)	1998	Modelled	IHME
6,464 (5,857 - 7,162)	1997	Modelled	IHME
6,410 (5,777 - 7,104)	1996	Modelled	IHME
6,311 (5,692 - 6,999)	1995	Modelled	IHME
6,224 (5,627 - 6,923)	1994	Modelled	IHME
6,130 (5,545 - 6,768)	1993	Modelled	IHME
5,894 (5,336 - 6,542)	1992	Modelled	IHME
5,800 (5,235 - 6,436)	1991	Modelled	IHME
5,801 (5,253 - 6,424)	1990	Modelled	IHME
14,251	2016	Modelled	WHO

Showing out of

Technical notes

Percent of liver cancer deaths attributable to HBV

National

Download

Value (%)	Year	Type	Source
17 (15 - 20)	2019	Modelled	IHME
17 (15 - 20)	2018	Modelled	IHME
17 (15 - 20)	2017	Modelled	IHME
17 (15 - 20)	2016	Modelled	IHME
17 (15 - 20)	2015	Modelled	IHME
17 (15 - 20)	2014	Modelled	IHME
17 (15 - 20)	2013	Modelled	IHME
18 (15 - 21)	2012	Modelled	IHME
18 (15 - 21)	2011	Modelled	IHME
18 (15 - 21)	2010	Modelled	IHME
18 (16 - 21)	2009	Modelled	IHME
19 (16 - 22)	2008	Modelled	IHME
20 (17 - 23)	2007	Modelled	IHME
20 (18 - 24)	2006	Modelled	IHME
21 (18 - 24)	2005	Modelled	IHME
21 (18 - 24)	2004	Modelled	IHME
21 (18 - 24)	2003	Modelled	IHME
21 (18 - 24)	2002	Modelled	IHME
21 (18 - 24)	2001	Modelled	IHME
21 (18 - 24)	2000	Modelled	IHME
21 (18 - 24)	1999	Modelled	IHME
21 (18 - 24)	1998	Modelled	IHME
21 (18 - 24)	1997	Modelled	IHME
21 (18 - 24)	1996	Modelled	IHME
21 (18 - 24)	1995	Modelled	IHME
21 (18 - 24)	1994	Modelled	IHME
21 (18 - 24)	1993	Modelled	IHME
21 (18 - 25)	1992	Modelled	IHME
22 (19 - 25)	1991	Modelled	IHME
22 (19 - 25)	1990	Modelled	IHME

Showing out of

Technical notes

Coverage of HepB birth dose

Newborns

Download

Value (%)	Year	Type	Source
80	2018	Survey/reported	WHO/UNICEF
80	2017	Survey/reported	WHO/UNICEF
82	2016	Survey/reported	WHO/UNICEF
91	2015	Survey/reported	WHO/UNICEF
88	2014	Survey/reported	WHO/UNICEF
89	2013	Survey/reported	WHO/UNICEF
90	2012	Survey/reported	WHO/UNICEF
91	2011	Survey/reported	WHO/UNICEF
92	2010	Survey/reported	WHO/UNICEF
92	2009	Survey/reported	WHO/UNICEF
93	2008	Survey/reported	WHO/UNICEF
94	2007	Survey/reported	WHO/UNICEF
95	2006	Survey/reported	WHO/UNICEF
94	2005	Survey/reported	WHO/UNICEF
92	2004	Survey/reported	WHO/UNICEF
91	2003	Survey/reported	WHO/UNICEF
93	2002	Survey/reported	WHO/UNICEF
95	2001	Survey/reported	WHO/UNICEF
99	2000	Survey/reported	WHO/UNICEF

Showing out of

Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants

Download

Value (%)	Year	Type	Source
83	2018	Survey/reported	WHO/UNICEF
93	2017	Survey/reported	WHO/UNICEF
89	2016	Survey/reported	WHO/UNICEF
96	2015	Survey/reported	WHO/UNICEF
96	2014	Survey/reported	WHO/UNICEF
96	2013	Survey/reported	WHO/UNICEF
96	2012	Survey/reported	WHO/UNICEF
98	2011	Survey/reported	WHO/UNICEF
96	2010	Survey/reported	WHO/UNICEF
99	2009	Survey/reported	WHO/UNICEF
96	2008	Survey/reported	WHO/UNICEF
99	2007	Survey/reported	WHO/UNICEF
99	2006	Survey/reported	WHO/UNICEF
98	2005	Survey/reported	WHO/UNICEF
96	2004	Survey/reported	WHO/UNICEF
97	2003	Survey/reported	WHO/UNICEF
92	2002	Survey/reported	WHO/UNICEF
91	2001	Survey/reported	WHO/UNICEF
94	2000	Survey/reported	WHO/UNICEF
84	1999	Survey/reported	WHO/UNICEF
13	1998	Survey/reported	WHO/UNICEF
6	1997	Survey/reported	WHO/UNICEF
15	1996	Survey/reported	WHO/UNICEF
10	1995	Survey/reported	WHO/UNICEF
4	1994	Survey/reported	WHO/UNICEF

Showing out of

Percent of PWID accessing OST

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
0	2016	Survey/reported	Harm Reduction International, 2016

HBV National Action Plan

HepB birth dose policy

Yes

Source: WHO

Year of birth dose introduction

1998

Source: WHO

Eligible for HBV generic medicines

Source: MPP

HCV National Action Plan

Source:

HCV elimination goal

Source:

Year of HCV elimination goal

2030

Source:

HCV testing policy

Risk-based

Source:

Eligible for HCV generic medicines

Source: MPP

At least one needle-syringe exchange program (NSP) operational

Source: Harm Reduction International

At least one opioid substitution therapy (OST) program operational

Source: Harm Reduction International

NSP in at least one prison

Source: Harm Reduction International

OST in at least one prison

Source: Harm Reduction International

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National

Download

Value (%)	Year	Type	Source
2.5 (2.02 - 3.10)	2019	Modelled	IHME
2.45 (1.98 - 3.05)	2018	Modelled	IHME
2.44 (1.96 - 3.04)	2017	Modelled	IHME
2.51 (2.03 - 3.12)	2016	Modelled	IHME
2.58 (2.08 - 3.20)	2015	Modelled	IHME
2.57 (2.07 - 3.19)	2014	Modelled	IHME
2.55 (2.06 - 3.17)	2013	Modelled	IHME
2.53 (2.04 - 3.14)	2012	Modelled	IHME
2.5 (2.02 - 3.11)	2011	Modelled	IHME
2.48 (2 - 3.09)	2010	Modelled	IHME
2.46 (1.98 - 3.06)	2009	Modelled	IHME
2.44 (1.96 - 3.04)	2008	Modelled	IHME
2.42 (1.94 - 3.01)	2007	Modelled	IHME
2.39 (1.92 - 2.98)	2006	Modelled	IHME
2.36 (1.89 - 2.95)	2005	Modelled	IHME
2.29 (1.84 - 2.86)	2004	Modelled	IHME
2.19 (1.75 - 2.73)	2003	Modelled	IHME
2.07 (1.66 - 2.58)	2002	Modelled	IHME
1.98 (1.59 - 2.47)	2001	Modelled	IHME
1.95 (1.56 - 2.42)	2000	Modelled	IHME
1.96 (1.57 - 2.44)	1999	Modelled	IHME
2.01 (1.60 - 2.50)	1998	Modelled	IHME
2.06 (1.64 - 2.57)	1997	Modelled	IHME
2.1 (1.68 - 2.63)	1996	Modelled	IHME
2.12 (1.69 - 2.66)	1995	Modelled	IHME
2.13 (1.69 - 2.66)	1994	Modelled	IHME
2.13 (1.69 - 2.67)	1993	Modelled	IHME
2.13 (1.69 - 2.67)	1992	Modelled	IHME
2.13 (1.69 - 2.67)	1991	Modelled	IHME
2.13 (1.69 - 2.67)	1990	Modelled	IHME
1.3 (0.10 - 1.30)	2014	Modelled	Gower et al, 2014

Showing out of

Prevalence of anti-HCV

National

Download

Value (%)	Year	Type	Source
1.38 (1.12 - 1.64)	2013	Survey/reported	Pereira LMMB et al, 2014
1.6 (1.10 - 1.60)	2014	Modelled	Gower et al, 2014

Showing out of

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
39.6 (24.90 - 56.40)	2019	Modelled	Granados-Garcia V et al, 2019
63.9 (60.50 - 67.30)	2001	Survey/reported	Caiaffa WT et al, 2006

Showing out of

HCV-related death rate

National

Download

Value (per 100,000)	Year	Type	Source
4.59 (4.11 - 5.11)	2019	Modelled	IHME
4.52 (4.09 - 5.03)	2018	Modelled	IHME
4.46 (4.05 - 4.95)	2017	Modelled	IHME
4.54 (4.11 - 5.05)	2016	Modelled	IHME
4.47 (4.05 - 4.97)	2015	Modelled	IHME
4.44 (4.03 - 4.92)	2014	Modelled	IHME
4.45 (4.03 - 4.92)	2013	Modelled	IHME
4.42 (4 - 4.90)	2012	Modelled	IHME
4.41 (3.99 - 4.89)	2011	Modelled	IHME
4.34 (3.93 - 4.81)	2010	Modelled	IHME
4.23 (3.85 - 4.67)	2009	Modelled	IHME
4.08 (3.70 - 4.52)	2008	Modelled	IHME
3.92 (3.57 - 4.32)	2007	Modelled	IHME
3.79 (3.45 - 4.19)	2006	Modelled	IHME
3.72 (3.37 - 4.10)	2005	Modelled	IHME
3.74 (3.40 - 4.13)	2004	Modelled	IHME
3.69 (3.34 - 4.08)	2003	Modelled	IHME
3.64 (3.31 - 4.02)	2002	Modelled	IHME
3.61 (3.27 - 3.99)	2001	Modelled	IHME
3.58 (3.25 - 3.95)	2000	Modelled	IHME
3.58 (3.25 - 3.95)	1999	Modelled	IHME
3.57 (3.25 - 3.94)	1998	Modelled	IHME
3.56 (3.23 - 3.91)	1997	Modelled	IHME
3.6 (3.26 - 3.95)	1996	Modelled	IHME
3.62 (3.27 - 3.97)	1995	Modelled	IHME
3.62 (3.28 - 3.99)	1994	Modelled	IHME
3.63 (3.30 - 3.98)	1993	Modelled	IHME
3.56 (3.22 - 3.91)	1992	Modelled	IHME
3.56 (3.22 - 3.91)	1991	Modelled	IHME
3.62 (3.27 - 3.98)	1990	Modelled	IHME

Showing out of

Technical notes

HCV-related deaths

National

Download

Value	Year	Type	Source
9,936 (8,915 - 11,066)	2019	Modelled	IHME
9,704 (8,787 - 10,805)	2018	Modelled	IHME
9,506 (8,626 - 10,546)	2017	Modelled	IHME
9,585 (8,682 - 10,667)	2016	Modelled	IHME
9,348 (8,481 - 10,402)	2015	Modelled	IHME
9,204 (8,347 - 10,194)	2014	Modelled	IHME
9,113 (8,271 - 10,083)	2013	Modelled	IHME
8,960 (8,117 - 9,930)	2012	Modelled	IHME
8,840 (8,011 - 9,803)	2011	Modelled	IHME
8,598 (7,800 - 9,535)	2010	Modelled	IHME
8,291 (7,543 - 9,162)	2009	Modelled	IHME
7,902 (7,172 - 8,753)	2008	Modelled	IHME
7,497 (6,827 - 8,263)	2007	Modelled	IHME
7,166 (6,517 - 7,907)	2006	Modelled	IHME
6,930 (6,291 - 7,650)	2005	Modelled	IHME
6,884 (6,256 - 7,597)	2004	Modelled	IHME
6,695 (6,071 - 7,403)	2003	Modelled	IHME
6,530 (5,927 - 7,211)	2002	Modelled	IHME
6,382 (5,782 - 7,050)	2001	Modelled	IHME
6,244 (5,665 - 6,884)	2000	Modelled	IHME
6,152 (5,587 - 6,785)	1999	Modelled	IHME
6,044 (5,497 - 6,657)	1998	Modelled	IHME
5,928 (5,379 - 6,517)	1997	Modelled	IHME
5,899 (5,346 - 6,481)	1996	Modelled	IHME
5,840 (5,275 - 6,413)	1995	Modelled	IHME
5,761 (5,212 - 6,344)	1994	Modelled	IHME
5,683 (5,169 - 6,228)	1993	Modelled	IHME
5,474 (4,958 - 6,022)	1992	Modelled	IHME
5,385 (4,878 - 5,921)	1991	Modelled	IHME
5,382 (4,864 - 5,924)	1990	Modelled	IHME
7,767	2016	Modelled	WHO

Showing out of

Technical notes

Percent of liver cancer deaths attributable to HCV

National

Download

Value (%)	Year	Type	Source
41 (37 - 45)	2019	Modelled	IHME
41 (37 - 45)	2018	Modelled	IHME
41 (37 - 45)	2017	Modelled	IHME
41 (37 - 45)	2016	Modelled	IHME
41 (37 - 45)	2015	Modelled	IHME
40 (36 - 44)	2014	Modelled	IHME
40 (36 - 44)	2013	Modelled	IHME
40 (36 - 44)	2012	Modelled	IHME
40 (36 - 44)	2011	Modelled	IHME
40 (36 - 44)	2010	Modelled	IHME
40 (36 - 44)	2009	Modelled	IHME
39 (35 - 43)	2008	Modelled	IHME
39 (35 - 42)	2007	Modelled	IHME
38 (34 - 42)	2006	Modelled	IHME
38 (34 - 42)	2005	Modelled	IHME
38 (34 - 41)	2004	Modelled	IHME
38 (34 - 41)	2003	Modelled	IHME
37 (34 - 41)	2002	Modelled	IHME
37 (34 - 41)	2001	Modelled	IHME
37 (33 - 41)	2000	Modelled	IHME
37 (34 - 41)	1999	Modelled	IHME
37 (34 - 41)	1998	Modelled	IHME
37 (34 - 41)	1997	Modelled	IHME
37 (34 - 41)	1996	Modelled	IHME
38 (34 - 42)	1995	Modelled	IHME
38 (34 - 42)	1994	Modelled	IHME
38 (34 - 42)	1993	Modelled	IHME
38 (34 - 42)	1992	Modelled	IHME
38 (34 - 41)	1991	Modelled	IHME
37 (34 - 41)	1990	Modelled	IHME

Showing out of

Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
0	2016	Survey/reported	Harm Reduction International, 2016

HBV National Action Plan

HepB birth dose policy

Yes

Source: WHO

Year of birth dose introduction

1998

Source: WHO

Eligible for HBV generic medicines

Source: MPP

HCV National Action Plan

Source:

HCV elimination goal

Source:

Year of HCV elimination goal

2030

Source:

HCV testing policy

Risk-based

Source:

Eligible for HCV generic medicines

Source: MPP

At least one needle-syringe exchange program (NSP) operational

Source: Harm Reduction International

At least one opioid substitution therapy (OST) program operational

Source: Harm Reduction International

NSP in at least one prison

Source: Harm Reduction International

OST in at least one prison

Source: Harm Reduction International

Overview

HCV elimination goal

Year of goal

2030

Prevalence (national)

Modelled

HBV (HBsAg+)

3.42 (%)

2019

(2.97 - 3.84(%))

IHME

HCV (RNA/cAg+)

2.5 (%)

2019

(2.02 - 3.1(%))

IHME

Survey/surveillance

HBV (HBsAg+)

7.9 (%)

1999

(7 - 8.7(%))

Silveira TR et al, 1999

HCV (anti-HCV)

1.38 (%)

2013

(1.12 - 1.64(%))

Pereira LMMB et al, 2014

Hepatitis related deaths (national)

Modelled

HBV

5,450

2019

(4,858 - 6,140)

IHME

Survey/surveillance

No data available

HBV chart

Modelled

HCV

9,936

2019

(8,915 - 11,066)

IHME

Survey/surveillance

No data available

HCV chart

Prevalence < 5

HBV

0.12 (%)

2019, latest modelled

(0.10 - 0.16(%))

IHME

Prevalence PWID

HCV

39.60 (%)

2019, latest modelled

(24.90 - 56.40(%))

Granados-Garcia V et al, 2019

Birth dose vaccination coverage (national)

Survey/surveillance

HBV

80 (%)

2018

WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available

Eligible for HBV generic medicines

Eligible for HCV generic medicines

Elimination champion

Carlos Varaldo

He demanded access to HCV medications in the public health system of Brazil leading to major discounts in pricing and increases in treatments from 15,000 to > 45,000 per year.